Long-term cost–effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Scopus)

Abstract

This study analyzes the incremental cost–effectiveness of Oncotype DX® testing to support adjuvant chemotherapy recommendations, versus current clinical practice, for patients with estrogen receptor-positive (ER+), node-negative or micrometastatic (pN1mic) early-stage breast cancer in The Netherlands. Methods: Markov model projecting distant recurrence, survival, quality-adjusted life years (QALYs) and healthcare costs over a 30-year time horizon. Results: Oncotype DX was projected to increase QALYs by 0.11 (0.07–0.58) and costs with €1236 (range: -€142–€1236) resulting in an incremental cost–effectiveness ratio of €11,236/QALY under the most conservative scenario. Conclusion: Reallocation of adjuvant chemotherapy based on Oncotype DX testing is most likely a cost-effective use of scarce resources, improving long-term survival and QALYs at marginal or lower costs
Original languageEnglish
Pages (from-to)433-445
JournalJournal of comparative effectiveness research
Volume4
Issue number5
DOIs
Publication statusPublished - 15 Apr 2015

Fingerprint

Quality-Adjusted Life Years
Costs and Cost Analysis
Adjuvant Chemotherapy
Survival
Estrogen Receptors
Health Care Costs
Netherlands
Breast Neoplasms
Recurrence

Keywords

  • METIS-311572
  • IR-97101

Cite this

@article{2d9d2d00ce6042f2bb5ee7f796cb3354,
title = "Long-term cost–effectiveness of Oncotype DX{\circledR} versus current clinical practice from a Dutch cost perspective",
abstract = "This study analyzes the incremental cost–effectiveness of Oncotype DX{\circledR} testing to support adjuvant chemotherapy recommendations, versus current clinical practice, for patients with estrogen receptor-positive (ER+), node-negative or micrometastatic (pN1mic) early-stage breast cancer in The Netherlands. Methods: Markov model projecting distant recurrence, survival, quality-adjusted life years (QALYs) and healthcare costs over a 30-year time horizon. Results: Oncotype DX was projected to increase QALYs by 0.11 (0.07–0.58) and costs with €1236 (range: -€142–€1236) resulting in an incremental cost–effectiveness ratio of €11,236/QALY under the most conservative scenario. Conclusion: Reallocation of adjuvant chemotherapy based on Oncotype DX testing is most likely a cost-effective use of scarce resources, improving long-term survival and QALYs at marginal or lower costs",
keywords = "METIS-311572, IR-97101",
author = "Kip, {Michelle Maria Aleida} and Helma Monteban and Steuten, {Lotte Maria Gertruda}",
year = "2015",
month = "4",
day = "15",
doi = "10.2217/cer.15.18",
language = "English",
volume = "4",
pages = "433--445",
journal = "Journal of comparative effectiveness research",
issn = "2042-6305",
publisher = "Future Medicine Ltd.",
number = "5",

}

Long-term cost–effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective. / Kip, Michelle Maria Aleida; Monteban, Helma; Steuten, Lotte Maria Gertruda.

In: Journal of comparative effectiveness research, Vol. 4, No. 5, 15.04.2015, p. 433-445.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Long-term cost–effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective

AU - Kip, Michelle Maria Aleida

AU - Monteban, Helma

AU - Steuten, Lotte Maria Gertruda

PY - 2015/4/15

Y1 - 2015/4/15

N2 - This study analyzes the incremental cost–effectiveness of Oncotype DX® testing to support adjuvant chemotherapy recommendations, versus current clinical practice, for patients with estrogen receptor-positive (ER+), node-negative or micrometastatic (pN1mic) early-stage breast cancer in The Netherlands. Methods: Markov model projecting distant recurrence, survival, quality-adjusted life years (QALYs) and healthcare costs over a 30-year time horizon. Results: Oncotype DX was projected to increase QALYs by 0.11 (0.07–0.58) and costs with €1236 (range: -€142–€1236) resulting in an incremental cost–effectiveness ratio of €11,236/QALY under the most conservative scenario. Conclusion: Reallocation of adjuvant chemotherapy based on Oncotype DX testing is most likely a cost-effective use of scarce resources, improving long-term survival and QALYs at marginal or lower costs

AB - This study analyzes the incremental cost–effectiveness of Oncotype DX® testing to support adjuvant chemotherapy recommendations, versus current clinical practice, for patients with estrogen receptor-positive (ER+), node-negative or micrometastatic (pN1mic) early-stage breast cancer in The Netherlands. Methods: Markov model projecting distant recurrence, survival, quality-adjusted life years (QALYs) and healthcare costs over a 30-year time horizon. Results: Oncotype DX was projected to increase QALYs by 0.11 (0.07–0.58) and costs with €1236 (range: -€142–€1236) resulting in an incremental cost–effectiveness ratio of €11,236/QALY under the most conservative scenario. Conclusion: Reallocation of adjuvant chemotherapy based on Oncotype DX testing is most likely a cost-effective use of scarce resources, improving long-term survival and QALYs at marginal or lower costs

KW - METIS-311572

KW - IR-97101

U2 - 10.2217/cer.15.18

DO - 10.2217/cer.15.18

M3 - Article

VL - 4

SP - 433

EP - 445

JO - Journal of comparative effectiveness research

JF - Journal of comparative effectiveness research

SN - 2042-6305

IS - 5

ER -